India's General Anti-Avoidance Rule (GAAR) has been one of the most closely watched areas of tax law, particularly for overseas investors with legacy inves
Most of the education about work-sponsored retirement plans comes from the employer or the plan provider. But what if you could be a source of knowledge too?
India's focus on port-led industrial development has created significant opportunities for businesses looking to establish manufacturing units, logistics h
Shareholders of Whitestone REIT (NYSE:WSR) approved the company’s proposed merger with and into AREG Wizard Intermediate LP at a virtual special meeting, according to remarks delivered during the meeting by David Holeman, Whitestone’s Chief Executive Officer and Trustee.
The vote clears the shareho
Unum Group (NYSE:UNM) said it has agreed to reinsure an additional portion of its long-term care insurance liabilities, marking the company’s third major external reinsurance transaction and its second involving long-term care.
On a conference call with analysts, President and CEO Rick McKenney sai
Most budgeting apps fail the same way: they’re either too rigid, too automatic, or too disconnected from how you actually think about money. You open them for two weeks, life gets busy, and by month three the app is
Jeff Bezos just opened Blue Origin to outside investors for the first time, and his own $2 billion investment may be the strongest signal yet that he believes the company's biggest growth is still ahead.
Teva Pharmaceutical Industries (NYSE:TEVA) said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy
Barchas maintains 211,763 residual shares through direct and indirect holdings following execution under a Rule 10b5-1 trading plan adopted in March 2026.
Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety
J.P. Morgan just outlined why a SpaceX-Tesla merger could make strategic sense on paper. It also got into why investors shouldn't mistake that for a likely deal.
